替诺福韦艾拉酚胺与恩曲他滨在中性粒细胞和血小板中的细胞药理学:HIV感染者与未感染者对比
本研究在13例HIV感染者和30例未感染者中,比较替诺福韦艾拉酚胺和恩曲他滨在干血斑、外周血单核细胞、中性粒细胞和血小板中的浓度。HIV感染者干血斑中替诺福韦二磷酸浓度较未感染者高48.9%,血小板中恩曲他滨三磷酸高36.3%,其他细胞类型无显著差异。
要点
- HIV感染者干血斑TFV-DP较未感染者高48.9%(95%CI 15.6%-91.9%)。
- HIV感染者血小板FTC-TP较未感染者高36.3%(95%CI 4.5%-77.7%)。
- TFV-DP和FTC-TP在中性粒细胞中半衰期最长,其次为PBMCs,再次为血小板。
核心结论
- 研究显示不同细胞类型间药物分布存在差异,且干血斑和血小板中的差异随血清状态而变化。
- 作者指出这些发现的机制和意义需要进一步研究。
研究设计与样本
- 研究纳入13例HIV感染者(96%男性)和30例未感染者(53%男性),均接受替诺福韦艾拉酚胺和恩曲他滨治疗。
- 从全血中分离干血斑、外周血单核细胞、中性粒细胞和血小板,采用LC-MS/MS定量TFV-DP和FTC-TP浓度。
- 使用线性回归模型控制服药时间、依从性和末次给药后时间,计算几何平均百分比差异(95%CI)和估计半衰期。
主要发现
- 与未感染者相比,HIV感染者干血斑中TFV-DP高48.9%(95%CI 15.6%-91.9%),血小板中FTC-TP高36.3%(95%CI 4.5%-77.7%)。
- HIV感染者血小板中TFV-DP也呈升高趋势,差异为43.5%(95%CI -3.24%-113%)。
- 其他细胞类型中TFV-DP和FTC-TP浓度按HIV状态无显著差异。
- TFV-DP和FTC-TP在中性粒细胞中半衰期最长,其次为PBMCs,再次为血小板。
- 按细胞体积标准化后,两种药物在HIV感染者和未感染者中累积量从高到低依次为PBMCs、中性粒细胞、血小板和红细胞。
关键数值与推荐
- HIV感染者干血斑TFV-DP较未感染者高48.9%(95%CI 15.6%-91.9%)。
- HIV感染者血小板FTC-TP较未感染者高36.3%(95%CI 4.5%-77.7%)。
- HIV感染者血小板TFV-DP较未感染者高43.5%(95%CI -3.24%-113%),未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies have primarily focused on nucleos(t)ide reverse transcriptase inhibitor pharmacology in peripheral blood mononuclear cells (PBMCs) and erythrocytes via dried blood spots (DBS), but not other major blood cells. OBJECTIVES: Our objectives were to describe and compare the concentrations of tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP) in DBS, PBMCs, neutrophils, and platelets in people with HIV (PWH) and people without HIV (PWOH). METHODS: DBS, PBMCs, neutrophils, and platelets were isolated from whole blood drawn from PWH and PWOH receiving tenofovir alafenamide and emtricitabine. TFV-DP and FTC-TP concentrations were quantified using LC-MS/MS in each cell type. Linear regression models controlled for time on drug, adherence, and time since last dose, where applicable, to determine geometric mean percent differences (95% confidence interval) by HIV status and estimated half-lives. RESULTS: Data were available in 13 PWH (96% male) and 30 PWOH (53% male). Compared with PWOH, TFV-DP in DBS was 48.9% (15.6%, 91.9%) higher and FTC-TP in platelets was 36.3% (4.5%, 77.7%) higher; TFV-DP in platelets also trended higher [43.5% (-3.24%, 113%)]. No other cell types significantly differed by HIV status. TFV-DP and FTC-TP demonstrated the longest half-lives in neutrophils, followed by PBMCs and then platelets. After normalizing to cell volume, both drugs accumulated from greatest to least in PBMCs, neutrophils, platelets, and erythrocytes across both PWH and PWOH. CONCLUSIONS: Our findings highlight differential drug disposition across cell types that also vary by serostatus in DBS and platelets. The mechanisms and implications of these findings require additional research.
引用
- Mainella VA, Branchford B, Nemkov T, et al. Cellular pharmacology of tenofovir alafenamide and emtricitabine in neutrophils and platelets in people with and without HIV. J Antimicrob Chemother. 2025. PMID: 40037647. doi:10.1093/jac/dkaf052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。